ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target
ACAD Analyst Ratings
Moderate Buy
10Buy5Hold0Sell
Based on 15 analysts giving stock ratings to ACADIA Pharmaceuticals in the past 3 months
ACAD Stock 12 Month Forecast
Average Price Target
MXN 587.78▲(51.10% Upside)Based on 15 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is MXN 587.78 with a high forecast of MXN 691.98 and a low forecast of MXN 430.15. The average price target represents a 51.10% change from the last price of MXN 389.00.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 691.98
AverageMXN 587.78
LowMXN 430.15
Highest Price TargetHighestMXN 691.98Average Price TargetMXN 587.78Lowest Price TargetLowestMXN 430.15
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | Needham | MXN 654.57 | buy | 68.27%Upside | Reiterated | 10/19/26 | ||
| Ashwani Verma | UBS | MXN 916.40→MXN 430.15 | hold | 10.58%Upside | Downgraded | 10/14/26 | ||
| Malcolm Hoffman | BMO Capital | MXN 635.87 | buy | 63.46%Upside | Reiterated | 10/12/26 | ||
| Tazeen Ahmad | Bank of America Securities | MXN 579.76 | buy | 49.04%Upside | Reiterated | 10/09/26 | ||
| Brian Abrahams | RBC Capital | MXN 691.98→MXN 673.27 | buy | 73.08%Upside | Reiterated | 10/08/26 | ||
| Yigal Nochomovitz | Citi | MXN 748.08→MXN 617.17 | buy | 58.66%Upside | Reiterated | 09/25/26 | ||
| Jason Butler | Citizens JMP | MXN 673.27→MXN 617.17 | buy | 58.66%Upside | Reiterated | 09/25/26 | ||
| Sumant Kulkarni | Canaccord Genuity | MXN 673.27 | buy | 73.08%Upside | Reiterated | 09/25/26 | ||
| David Hoang | Deutsche Bank | MXN 710.68→MXN 579.76 | buy | 49.04%Upside | Reiterated | 09/25/26 | ||
| Ananda Ghosh | H.C. Wainwright | MXN 691.98→MXN 617.17 | buy | 58.66%Upside | Reiterated | 09/25/26 | ||
| Sean Laaman | Morgan Stanley | MXN 504.96→MXN 523.66 | hold | 34.62%Upside | Assigned | 08/25/26 | ||
| Ritu Baral | TD Cowen | MXN 691.98 | buy | 77.89%Upside | Assigned | 08/05/26 | ||
| Paul Matteis | Stifel Nicolaus | MXN 467.55 | hold | 20.19%Upside | Reiterated | 08/05/26 | ||
| Matthew Hershenhorn | Oppenheimer | MXN 430.15→MXN 467.55 | hold | 20.19%Upside | Reiterated | 08/05/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 08/04/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Ami Fadia | 10/19/26 | MXN 654.57 | buy | 68.27%Upside | Reiterated | Needham | ||
| Ashwani Verma | 10/14/26 | MXN 916.40→MXN 430.15 | hold | 10.58%Upside | Downgraded | UBS | ||
| Malcolm Hoffman | 10/12/26 | MXN 635.87 | buy | 63.46%Upside | Reiterated | BMO Capital | ||
| Tazeen Ahmad | 10/09/26 | MXN 579.76 | buy | 49.04%Upside | Reiterated | Bank of America Securities | ||
| Brian Abrahams | 10/08/26 | MXN 691.98→MXN 673.27 | buy | 73.08%Upside | Reiterated | RBC Capital | ||
| Yigal Nochomovitz | 09/25/26 | MXN 748.08→MXN 617.17 | buy | 58.66%Upside | Reiterated | Citi | ||
| Jason Butler | 09/25/26 | MXN 673.27→MXN 617.17 | buy | 58.66%Upside | Reiterated | Citizens JMP | ||
| Sumant Kulkarni | 09/25/26 | MXN 673.27 | buy | 73.08%Upside | Reiterated | Canaccord Genuity | ||
| David Hoang | 09/25/26 | MXN 710.68→MXN 579.76 | buy | 49.04%Upside | Reiterated | Deutsche Bank | ||
| Ananda Ghosh | 09/25/26 | MXN 691.98→MXN 617.17 | buy | 58.66%Upside | Reiterated | H.C. Wainwright | ||
| Sean Laaman | 08/25/26 | MXN 504.96→MXN 523.66 | hold | 34.62%Upside | Assigned | Morgan Stanley | ||
| Ritu Baral | 08/05/26 | MXN 691.98 | buy | 77.89%Upside | Assigned | TD Cowen | ||
| Paul Matteis | 08/05/26 | MXN 467.55 | hold | 20.19%Upside | Reiterated | Stifel Nicolaus | ||
| Matthew Hershenhorn | 08/05/26 | MXN 430.15→MXN 467.55 | hold | 20.19%Upside | Reiterated | Oppenheimer | ||
| Unknown AnalystNot Ranked | 08/04/26 | ― | hold | ― | Reiterated | Guggenheim |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering ACADIA Pharmaceuticals
3 Months
Success Rate9/13 ratings generated profit
69%
Average Return
+8.76%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +8.76% per trade.
1 Year
Success Rate16/29 ratings generated profit
55%
Average Return
+7.27%
Copying Jason Butler's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +7.27% per trade.
2 Years
Success Rate6/13 ratings generated profit
46%
Average Return
+5.19%
Copying Tessa Romero's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of +5.19% per trade.
ACAD Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 1 | 7 | 12 |
| Buy | 13 | 16 | 29 | 26 | 20 |
| Hold | 4 | 6 | 9 | 9 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 23 | 28 | 39 | 42 | 40 |
In the current month, ACAD has received 32 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. ACAD average Analyst price target in the past 3 months is 587.78.
ACAD Financial Forecast
HighMXN 5.45
ConsensusMXN 3.74
LowMXN 2.07
ACAD Earnings Forecast
Next quarter’s earnings estimate for ACAD is MXN 3.74 with a range of MXN 2.07 to MXN 5.45. The previous quarter’s EPS was MXN 3.38. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 6.36B
ConsensusMXN 6.25B
LowMXN 6.11B
ACAD Sales Forecast
Next quarter’s sales forecast for ACAD is MXN 6.25B with a range of MXN 6.11B to MXN 6.36B. The previous quarter’s sales results were MXN 5.79B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ACAD Stock Forecast FAQ
What is MX:ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is Mex$587.78.
What is MX:ACAD’s upside potential, based on the analysts’ average price target?
ACADIA Pharmaceuticals has 51.10% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACADIA Pharmaceuticals a Buy, Sell or Hold?
ACADIA Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 5 hold ratings and 0 sell ratings.
What is ACADIA Pharmaceuticals’s share price target?
The average share price target for ACADIA Pharmaceuticals is Mex$587.78. This is based on 15 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$691.98, and the lowest forecast is Mex$430.15. The average share price target represents a 51.10% increase from the current price of Mex$389.
What do analysts say about ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Street analysts.
How can I buy shares of ACADIA Pharmaceuticals?
To buy shares of MX:ACAD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
